Stem cell therapy shows promise restoring vision

Scientists have shared promising findings from a phase I clinical trial centred on an advanced stem cell therapy for repairing cornea damage.

The innovative therapy, known as cultivated autologous limbal epithelial cell transplantation (CALEC), demonstrates both safety and short-term efficacy in patients suffering from severe cornea damage caused by chemical burns.

Published in the journal Science Advances, the team’s study showcases the potential of CALEC in transforming the lives of patients previously deemed untreatable due to their extensive cornea injuries.

Nullam et interdum sapien, eu facilisis erat. Etiam eget quam nisi. Integer imperdiet eros vel lorem pellentesque, non ornare libero aliquam. Phasellus nec urna molestie, pellentesque nisi at, volutpat odio. Mauris pulvinar efficitur neque at pretium. Nunc euismod turpis ante, et porttitor diam auctor sed. Ut erat metus, tincidunt a malesuada nec, blandit ut felis. Nullam pulvinar ac dolor at euismod. Curabitur scelerisque ac urna in cursus. Nulla nisi elit, consectetur a sem ac, laoreet condimentum massa
Register for free or to unlock this article
To gain full access to the only resource for industry news, simply register for free.
Already registered?
Connecting Surgeons.
Shaping the future.
connecting surgeons. shaping the future
linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram